The overarching aim of NIMIA is the introduction of novel digital biomarkers forming prognostic models that can identify the Multiple Sclerosis (MS) progression from the pre-clinical phase to early MS and later stages.
The long-term goal of NIMIA is to develop, apply and validate a set of digital biomarkers that will allow comprehensive monitoring of disease activity, including the timely detection of relapses, the transitioning of RRMS to SPMS, and the continuous assessment of important health-related variables. To apply and validate a set of digital biomarkers that will allow comprehensive monitoring of disease activity, including the timely detection of relapses, the transitioning of RRMS to SPMS, and the continuous assessment of important health-related variables.
